Aadi Bioscience Inc
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa… Read more
Aadi Bioscience Inc (AADI) - Total Liabilities
Latest total liabilities as of December 2024: $17.84 Million USD
Based on the latest financial reports, Aadi Bioscience Inc (AADI) has total liabilities worth $17.84 Million USD as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Aadi Bioscience Inc - Total Liabilities Trend (2009–2024)
This chart illustrates how Aadi Bioscience Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Aadi Bioscience Inc Competitors by Total Liabilities
The table below lists competitors of Aadi Bioscience Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhong An Group Limited
F:35Z
|
Germany | €18.61 Billion |
|
Chang Ho Fibre Corp
TW:1468
|
Taiwan | NT$1.66 Billion |
|
Mustang Industrial
TWO:5460
|
Taiwan | NT$78.52 Million |
|
KMH Hitech Co. Ltd
KQ:052900
|
Korea | ₩79.08 Billion |
|
Duro Felguera
MC:MDF
|
Spain | €460.16 Million |
|
ODTech Co. Ltd
KQ:080520
|
Korea | ₩7.53 Billion |
|
First Ship Lease Trust
PINK:FSLUF
|
USA | $532.00K |
|
Favelle Favco Bhd
KLSE:7229
|
Malaysia | RM601.98 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down Aadi Bioscience Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aadi Bioscience Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aadi Bioscience Inc (2009–2024)
The table below shows the annual total liabilities of Aadi Bioscience Inc from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $17.84 Million | -34.48% |
| 2023-12-31 | $27.23 Million | +5.29% |
| 2022-12-31 | $25.86 Million | +20.25% |
| 2021-12-31 | $21.50 Million | -31.20% |
| 2020-12-31 | $31.26 Million | +818.93% |
| 2019-12-31 | $3.40 Million | -37.67% |
| 2018-12-31 | $5.46 Million | +51.91% |
| 2017-12-31 | $3.59 Million | -75.82% |
| 2016-12-31 | $14.86 Million | +587.89% |
| 2015-12-31 | $2.16 Million | +1247.36% |
| 2014-12-31 | $160.30K | +20.51% |
| 2013-12-31 | $133.03K | +28.34% |
| 2012-12-31 | $103.65K | +38.56% |
| 2011-12-31 | $74.80K | +6.27% |
| 2010-12-31 | $70.39K | +122.66% |
| 2009-12-31 | $31.61K | -- |